Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ALLERGY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ALLERGY TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ALLERGY TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.1.1 PREVALENCE OF ASTHMA
5.1.2 PREVALENCE OF VENOM ALLERGY
5.1.3 PREVALENCE OF ALLERGIC RHINITIS
5.1.4 PREVALENCE OF CONJUNCTIVITIS
5.1.5 PREVALENCE OF ATOPIC DERMATITIS
5.1.6 PREVALENCE OF URTICARIA
5.1.7 PREVALENCE OF ANAPHYLAXIS
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DOCTORS
6.8 INTERVIEWS WITH SALES EXECUTIVES
6.9 INTERVIEWS WITH PHARMACIES
6.1 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINTS
10.3 OPPORTUNITIES
10.4 CHALLENGES
11 GLOBAL ALLERGY TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CORTICOSTEROIDS
11.2.1.1. BY DRUGS
11.2.1.1.1. BUDESONIDE
11.2.1.1.1.1 MARKET VALUE (USD MN)
11.2.1.1.1.2 MAKET VOLUME (IU)
11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.2. FULTICASONE FUROATE
11.2.1.1.2.1 MARKET VALUE (USD MN)
11.2.1.1.2.2 MAKET VOLUME (IU)
11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.3. FLUTICASONE PROPIONATE
11.2.1.1.3.1 MARKET VALUE (USD MN)
11.2.1.1.3.2 MAKET VOLUME (IU)
11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.4. MOMETASONE
11.2.1.1.4.1 MARKET VALUE (USD MN)
11.2.1.1.4.2 MAKET VOLUME (IU)
11.2.1.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.5. TRIAMCINOLONE
11.2.1.1.5.1 MARKET VALUE (USD MN)
11.2.1.1.5.2 MAKET VOLUME (IU)
11.2.1.1.5.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.6. BECLOMETHASONE
11.2.1.1.6.1 MARKET VALUE (USD MN)
11.2.1.1.6.2 MAKET VOLUME (IU)
11.2.1.1.6.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.7. CICLESONIDE
11.2.1.1.7.1 MARKET VALUE (USD MN)
11.2.1.1.7.2 MAKET VOLUME (IU)
11.2.1.1.7.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.8. FLUOROMETHOLONE
11.2.1.1.8.1 MARKET VALUE (USD MN)
11.2.1.1.8.2 MAKET VOLUME (IU)
11.2.1.1.8.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.9. PREDNISOLONE
11.2.1.1.9.1 MARKET VALUE (USD MN)
11.2.1.1.9.2 MAKET VOLUME (IU)
11.2.1.1.9.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.10. PREDNISONE
11.2.1.1.10.1 MARKET VALUE (USD MN)
11.2.1.1.10.2 MAKET VOLUME (IU)
11.2.1.1.10.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.11. METHYLPREDNISOLONE
11.2.1.1.11.1 MARKET VALUE (USD MN)
11.2.1.1.11.2 MAKET VOLUME (IU)
11.2.1.1.11.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.12. BETAMETHASONE
11.2.1.1.12.1 MARKET VALUE (USD MN)
11.2.1.1.12.2 MAKET VOLUME (IU)
11.2.1.1.12.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.13. DESONIDE
11.2.1.1.13.1 MARKET VALUE (USD MN)
11.2.1.1.13.2 MAKET VOLUME (IU)
11.2.1.1.13.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.14. HYDROCORTISONE
11.2.1.1.14.1 MARKET VALUE (USD MN)
11.2.1.1.14.2 MAKET VOLUME (IU)
11.2.1.1.14.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.15. OTHERS
11.2.1.2. BY ROUTE OF ADMINISTRATIONS
11.2.1.2.1. ORAL
11.2.1.2.1.1 PILLS
11.2.1.2.1.2 TABLETS
11.2.1.2.1.3 CAPSULES
11.2.1.2.1.4 OTHERS
11.2.1.2.2. TOPICALS
11.2.1.2.2.1 GELS
11.2.1.2.2.2 NASAL SPRAYS
11.2.1.2.2.3 EYE DROPS
11.2.1.2.2.4 CREAM
11.2.1.2.2.5 OTHERS
11.2.1.2.3. PARENTERAL
11.2.1.2.3.1 SOLUTIONS
11.2.1.2.3.2 SUSPENTIONS
11.2.1.2.3.3 OTHERS
11.2.1.3. BY DRUG TYPE
11.2.1.3.1. BRANDED
11.2.1.3.2. GENERICS
11.2.2 ANTIHISTAMINES
11.2.2.1. BY DRUGS
11.2.2.1.1. IORATADINE
11.2.2.1.1.1 MARKET VALUE (USD MN)
11.2.2.1.1.2 MAKET VOLUME (IU)
11.2.2.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.2. CETIRIZINE
11.2.2.1.2.1 MARKET VALUE (USD MN)
11.2.2.1.2.2 MAKET VOLUME (IU)
11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.3. DIPHENHYDRAMINE
11.2.2.1.3.1 MARKET VALUE (USD MN)
11.2.2.1.3.2 MAKET VOLUME (IU)
11.2.2.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.4. CHLORPHENIRAMINE
11.2.2.1.4.1 MARKET VALUE (USD MN)
11.2.2.1.4.2 MAKET VOLUME (IU)
11.2.2.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.5. LEVOCETIRIZINE
11.2.2.1.5.1 MARKET VALUE (USD MN)
11.2.2.1.5.2 MAKET VOLUME (IU)
11.2.2.1.5.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.6. FEXOFENADINE
11.2.2.1.6.1 MARKET VALUE (USD MN)
11.2.2.1.6.2 MAKET VOLUME (IU)
11.2.2.1.6.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.7. DESLORATADINE
11.2.2.1.7.1 MARKET VALUE (USD MN)
11.2.2.1.7.2 MAKET VOLUME (IU)
11.2.2.1.7.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.8. KETOTIFEN
11.2.2.1.8.1 MARKET VALUE (USD MN)
11.2.2.1.8.2 MAKET VOLUME (IU)
11.2.2.1.8.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.9. OLOPATADINE
11.2.2.1.9.1 MARKET VALUE (USD MN)
11.2.2.1.9.2 MAKET VOLUME (IU)
11.2.2.1.9.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.10. PHENIRAMINE
11.2.2.1.10.1 MARKET VALUE (USD MN)
11.2.2.1.10.2 MAKET VOLUME (IU)
11.2.2.1.10.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.11. AZELASTINE
11.2.2.1.11.1 MARKET VALUE (USD MN)
11.2.2.1.11.2 MAKET VOLUME (IU)
11.2.2.1.11.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.12. OTHERS
11.2.2.2. BY ROUTE OF ADMINISTRATIONS
11.2.2.2.1. ORAL
11.2.2.2.1.1 PILLS
11.2.2.2.1.2 TABLETS
11.2.2.2.1.3 CAPSULES
11.2.2.2.1.4 OTHERS
11.2.2.2.2. TOPICALS
11.2.2.2.2.1 GELS
11.2.2.2.2.2 NASAL SPRAYS
11.2.2.2.2.3 EYE DROPS
11.2.2.2.2.4 CREAM
11.2.2.2.2.5 OTHERS
11.2.2.2.3. PARENTERAL
11.2.2.2.3.1 SOLUTIONS
11.2.2.2.3.2 SUSPENTIONS
11.2.2.2.3.3 OTHERS
11.2.2.3. BY DRUG TYPE
11.2.2.3.1. BRANDED
11.2.2.3.2. GENERICS
11.2.3 DECONGESTANTS
11.2.3.1. BY DRUGS
11.2.3.1.1. PSEDOEPHRINE
11.2.3.1.1.1 MARKET VALUE (USD MN)
11.2.3.1.1.2 MARKET VOLUME (SU)
11.2.3.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.2. PHENYLEPHRINE
11.2.3.1.2.1 MARKET VALUE (USD MN)
11.2.3.1.2.2 MARKET VOLUME (SU)
11.2.3.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.3. OXYMETAZOLINE
11.2.3.1.3.1 MARKET VALUE (USD MN)
11.2.3.1.3.2 MARKET VOLUME (SU)
11.2.3.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.4. PSEUDOEPHEDRINE
11.2.3.1.4.1 MARKET VALUE (USD MN)
11.2.3.1.4.2 MARKET VOLUME (SU)
11.2.3.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.5. TETRAHYDROZOLINE
11.2.3.1.5.1 MARKET VALUE (USD MN)
11.2.3.1.5.2 MAKET VOLUME (IU)
11.2.3.1.5.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.6. OTHERS
11.2.3.2. BY ROUTE OF ADMINISTRATIONS
11.2.3.2.1. ORAL
11.2.3.2.1.1 PILLS
11.2.3.2.1.2 TABLETS
11.2.3.2.1.3 CAPSULES
11.2.3.2.1.4 OTHERS
11.2.3.2.2. TOPICALS
11.2.3.2.2.1 GELS
11.2.3.2.2.2 NASAL SPRAYS
11.2.3.2.2.3 EYE DROPS
11.2.3.2.2.4 CREAM
11.2.3.2.2.5 OTHERS
11.2.3.2.3. PARENTERAL
11.2.3.2.3.1 SOLUTIONS
11.2.3.2.3.2 SUSPENTIONS
11.2.3.2.3.3 OTHERS
11.2.3.3. BY DRUG TYPE
11.2.3.3.1. BRANDED
11.2.3.3.2. GENERICS
11.3 MAST CELL STABILIZERS
11.3.1.1. BY DRUGS
11.3.1.1.1. CROMOLYN
11.3.1.1.1.1 MARKET VALUE (USD MN)
11.3.1.1.1.2 MAKET VOLUME (IU)
11.3.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.2. LODOXAMIDE
11.3.1.1.2.1 MARKET VALUE (USD MN)
11.3.1.1.2.2 MAKET VOLUME (IU)
11.3.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.3. NEDOCROMIL
11.3.1.1.3.1 MARKET VALUE (USD MN)
11.3.1.1.3.2 MAKET VOLUME (IU)
11.3.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.4. OTHERS
11.3.1.2. BY DRUG TYPE
11.3.1.2.1. GENERICS
11.3.1.2.2. BRANDED
11.3.1.3. BY ROUTE OF ADMINISTRATIONS
11.3.1.3.1. ORAL
11.3.1.3.1.1 PILLS
11.3.1.3.1.2 TABLETS
11.3.1.3.1.3 CAPSULES
11.3.1.3.1.4 OTHERS
11.3.1.3.2. TOPICALS
11.3.1.3.2.1 GELS
11.3.1.3.2.2 NASAL SPRAYS
11.3.1.3.2.3 EYE DROPS
11.3.1.3.2.4 CREAM
11.3.1.3.2.5 OTHERS
11.3.1.3.3. PARENTERAL
11.3.1.3.3.1 SOLUTIONS
11.3.1.3.3.2 SUSPENTIONS
11.3.1.3.3.3 OTHERS
11.3.1.4. BY DRUG TYPE
11.3.1.4.1. BRANDED
11.3.1.4.2. GENERICS
11.4 EPINEPHRINE SHOTS
11.4.1.1. ADRENACLICK
11.4.1.1.1. MARKET VALUE (USD MN)
11.4.1.1.2. MAKET VOLUME (IU)
11.4.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.2. AUVI-Q
11.4.1.2.1. MARKET VALUE (USD MN)
11.4.1.2.2. MAKET VOLUME (IU)
11.4.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3. EPIPEN
11.4.1.3.1. MARKET VALUE (USD MN)
11.4.1.3.2. MAKET VOLUME (IU)
11.4.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.4. EPIPEN JR
11.4.1.4.1. MARKET VALUE (USD MN)
11.4.1.4.2. MAKET VOLUME (IU)
11.4.1.4.3. AVERAGE SELLING PRICE (USD)
11.4.1.5. OTHERS
11.4.2 LEUKOTRIENE INHIBITORS
11.4.2.1. BY DRUGS
11.4.2.1.1. MOTELUKAST
11.4.2.1.1.1 MARKET VALUE (USD MN)
11.4.2.1.1.2 MAKET VOLUME (IU)
11.4.2.1.1.3 AVERAGE SELLING PRICE (USD)
11.4.2.1.2. ZAFIRLUKAST
11.4.2.1.2.1 MARKET VALUE (USD MN)
11.4.2.1.2.2 MAKET VOLUME (IU)
11.4.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.1.3. OTHERS
11.4.2.2. BY DRUG TYPE
11.4.2.2.1. BRANDED
11.4.2.2.2. GENERICS
11.4.3 OTHERS
11.5 IMMUNOTHERAPY
11.5.1 SUBLINGUAL IMMUNOTHERAPY (SLIT)
11.5.2 SUBCUTANEOUS IMMUNOTHERAPY (SCIT)
12 GLOBAL ALLERGY TREATMENT MARKET, BY DISEASE TYPE
12.1 OVERVIEW
12.2 FOOD ALLERGIES
12.2.1 MILK ALLERGY
12.2.2 EGG ALLLERGY
12.2.3 FISH ALLERGY
12.2.4 PEANUTS ALLERGY
12.2.5 WHEAT ALLERGY
12.2.6 SOYABEAN ALLERGY
12.2.7 SEASAME ALLERGY
12.2.8 TREE NUT ALLERGY
12.2.9 CRUSTACEAN SHELLFISH ALLERGY
12.2.10 OTHERS
12.3 DRUG ALLERGY
12.3.1 PENICILLIN ALLERGY
12.3.2 SULFONAMIDES ALLERGY
12.3.3 ANTICONVULSANT ALLERGY
12.3.4 NSAIDS ALLERGY
12.3.5 CHEMOTHERAPY ALLERGY
12.3.6 OTHERS
12.4 PET ALLERGY
12.4.1 CATS ALLERGY
12.4.2 DOG ALLERGY
12.4.3 OTYHERS
12.5 INSECT ALLERGY
12.5.1 MOSQUITOES ALLERGY
12.5.2 KISSING BUGS ALLERGY
12.5.3 BED BUGS ALLERGY
12.5.4 FLEAS ALLERGY
12.5.5 OTHERS
12.6 LATEX ALLERGY
12.6.1 IMMUNOGLOBULIN E (IGE ) MEDIATED
12.6.2 CONTACT DERMATITIS
12.7 MOLD ALLERGY
12.7.1 ALTERNARIA ALLERGY
12.7.2 ASPERGILLUS ALLERGY
12.7.3 CLADOSPORIUM ALLERGY
12.7.4 OTHERS
12.8 POLLEN ALLERGY
12.9 SKIN ALLERGY
12.9.1 ATOPIC DERMATITIS
12.9.2 URTICARIA
12.1 ASTHMA
12.11 ALLERGIC RHINITIS
12.12 CONJUNCTIVITIS
12.13 OTHERS
13 GLOBAL ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 PILLS
13.2.2 TABLETS
13.2.3 CAPSULES
13.2.4 OTHERS
13.3 TOPICALS
13.3.1 GELS
13.3.2 NASAL SPRAYS
13.3.3 EYE DROPS
13.3.4 CREAM
13.3.5 OTHERS
13.4 PARENTERAL
13.4.1 SOLUTIONS
13.4.2 SUSPENTIONS
13.4.3 OTHERS
14 GLOBAL ALLERGY TREATMENT MARKET, BY DRUG TYPE
14.1 BRANDED
14.2 GENERICS
15 GLOBAL ALLERGY TREATMENT MARKET, BY MODE OF PURCHASE
15.1 OVERVIEW
15.2 OVER THE COUNTER
15.3 PRESCRIPTION
16 GLOBAL ALLERGY TREATMENT MARKET, BY AGE GROUP
16.1 OVERVIEW
16.2 PEDIATRIC
16.3 ADULTS
16.4 GERIATRIC
17 GLOBAL ALLERGY TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITAL
17.3 CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 GLOBAL ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 ONLINE PHARMACY
18.4 RETAIL PHARMACY
18.5 OTHERS
19 GLOBAL ALLERGY TREATMENT MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 MERGERS & ACQUISITIONS
19.3 NEW PRODUCT DEVELOPMENT & APPROVALS
19.4 EXPANSIONS
19.5 REGULATORY CHANGES
19.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL ALLERGY TREATMENT MARKET, BY GEOGRAPHY
20.1 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.2 NORTH AMERICA
20.2.1 U.S.
20.2.1.1. U.S. GOUT THERAPEUTICS MARKET, BY TREATMENT
20.2.1.2. U.S. GOUT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
20.2.1.3. U.S. GOUT THERAPEUTICS MARKET, BY END USER
20.2.1.4. U.S. GOUT THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
20.3 CANADA
20.4 MEXICO
20.5 EUROPE
20.5.1 GERMANY
20.5.2 FRANCE
20.5.3 U.K.
20.5.4 FINLAND
20.5.5 DENMARK
20.5.6 NORWAY
20.5.7 POLAND
20.5.8 ITALY
20.5.9 SPAIN
20.5.10 RUSSIA
20.5.11 TURKEY
20.5.12 BELGIUM
20.5.13 NETHERLANDS
20.5.14 SWITZERLAND
20.5.15 SWEDEN
20.5.16 REST OF EUROPE
20.6 ASIA-PACIFIC
20.6.1 JAPAN
20.6.2 CHINA
20.6.3 SOUTH KOREA
20.6.4 INDIA
20.6.5 SINGAPORE
20.6.6 THAILAND
20.6.7 INDONESIA
20.6.8 MALAYSIA
20.6.9 PHILIPPINES
20.6.10 AUSTRALIA
20.6.11 NEW ZEALAND
20.6.12 VIETNAM
20.6.13 TAIWAN
20.6.14 REST OF ASIA-PACIFIC
20.6.15
20.7 SOUTH AMERICA
20.7.1 BRZIL
20.7.2 ARGENTINA
20.7.3 REST OF SOUTH AMERICA
20.8 MIDDLE EAST AND AFRICA
20.8.1 SOUTH AFRICA
20.8.2 SAUDI ARABIA
20.8.3 UAE
20.8.4 EGYPT
20.8.5 KUWAIT
20.8.6 OMAN
20.8.7 ISRAEL
20.8.8 BAHRAIN
20.8.9 REST OF MIDDLE EAST AND AFRICA
20.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
21 GLOBAL ALLERGY TREATMENT MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL ALLERGY TREATMENT MARKET, COMPANY PROFILE
22.1 SANOFI
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 GLAXOSMITHKLINE PLC
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 PFIZER INC.
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 JANSSEN GLOBAL SERVICES, LLC.
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 ABBVIE
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENTS
22.6 NOVARTIS AG
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPMENTS
22.7 LUPIN
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPMENTS
22.8 AMNEAL PHARMACEUTICALS LLC
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 DR. REDDY’S LABORATORIES LTD.
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPMENTS
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPMENTS
22.11 TEVA PHARMACEUTICAL INDUSTRIES LTD
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 MYLAN N.V
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENTS
22.13 ZYDUS CADILA
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPMENTS
22.14 CIPLA
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENTS
22.15 GENENTECH, USA INC.
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPMENTS
22.16 STALLERGENES GREER
22.16.1 COMPANY OVERVIEW
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPMENTS
22.17 ALK
22.17.1 COMPANY OVERVIEW
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPMENTS
22.18 ALLERGY THERAPEUTICS
22.18.1 COMPANY OVERVIEW
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPMENTS
22.19 ADAMIS PHARMACEUTICALS CORPORATION
22.19.1 COMPANY OVERVIEW
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPMENTS
22.2 HOLLISTERSTIER ALLERGY. A JUBILANT PHARMA COMPANY
22.20.1 COMPANY OVERVIEW
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPMENTS
22.21 HAL ALLERGY B.V.
22.21.1 COMPANY OVERVIEW
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPMENTS
22.22 SUNOVION
22.22.1 COMPANY OVERVIEW
22.22.2 REVENUE ANALYSIS
22.22.3 GEOGRAPHIC PRESENCE
22.22.4 PRODUCT PORTFOLIO
22.22.5 RECENT DEVELOPMENTS
22.23 APOTEX CORPORATION
22.23.1 COMPANY OVERVIEW
22.23.2 PRODUCT PORTFOLIO
22.23.3 REVENUE ANALYSIS
22.23.4 GEOGRAPHIC PRESENCE
22.23.5 PRODUCT PORTFOLIO
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
